login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ENLIVEX THERAPEUTICS LTD (ENLV) Stock News
NASDAQ:ENLV - Nasdaq -
IL0011319527
-
Common Stock
- Currency: USD
1.3147
-0.51 (-27.76%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ENLV Latest News, Press Relases and Analysis
All
Press Releases
an hour ago - By: Chartmill
- Mentions:
TNXP
XNET
TPIC
SNGX
...
What's going on in today's session
3 hours ago - By: Chartmill
- Mentions:
TNXP
XNET
TPIC
SNGX
...
Monday's session: top gainers and losers
3 hours ago - By: Benzinga
- Mentions:
TNXP
SNGX
USBC
BNR
...
12 Health Care Stocks Moving In Monday's Intraday Session
5 hours ago - By: Chartmill
- Mentions:
TNXP
XNET
TPIC
SNGX
...
Let's uncover which stocks are experiencing notable gaps during today's session.
8 hours ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
8 hours ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
4 days ago - By: Enlivex Therapeutics Ltd
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
4 days ago - By: Enlivex Therapeutics Ltd
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
21 days ago - By: Enlivex Therapeutics Ltd
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
21 days ago - By: Enlivex Therapeutics Ltd
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
2 months ago - By: ACCESS Newswire
- Mentions:
FMST
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
2 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
3 months ago - By: Enlivex Therapeutics Ltd
Enlivex Selected to Present at Israeli BioMed 2025 Conference
4 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
4 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
4 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
5 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
5 months ago - By: Enlivex Therapeutics Ltd
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
5 months ago - By: Enlivex Therapeutics Ltd
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
6 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
6 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
6 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
6 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
6 months ago - By: Enlivex Therapeutics Ltd
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
6 months ago - By: Enlivex Therapeutics Ltd
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
6 months ago - By: ACCESS Newswire
- Mentions:
ASPI
NVA
BFRG
GRRR
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis
8 months ago - By: Enlivex Therapeutics Ltd
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
8 months ago - By: Enlivex Therapeutics Ltd
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
9 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
9 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
9 months ago - By: Enlivex Therapeutics Ltd
Enlivex Adopts Bitcoin Treasury Reserve Strategy
9 months ago - By: Enlivex Therapeutics Ltd
Enlivex Adopts Bitcoin Treasury Reserve Strategy
9 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
9 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
9 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
10 months ago - By: Enlivex Therapeutics Ltd
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
Please enable JavaScript to continue using this application.